Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

J Urol. 2005 Feb;173(2):441. doi: 10.1097/01.ju.0000148855.17830.97.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use
  • Biphenyl Compounds
  • Humans
  • Male
  • Prostate-Specific Antigen / blood*
  • Prostate-Specific Antigen / drug effects*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy
  • Tetrazoles / pharmacology*
  • Tetrazoles / therapeutic use
  • Treatment Failure

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antineoplastic Agents, Hormonal
  • Benzimidazoles
  • Biphenyl Compounds
  • Tetrazoles
  • Prostate-Specific Antigen
  • candesartan